DiaMedica Announces Stock Option Grant

DiaMedica Inc. (TSX VENTURE:DMA), a clinical stage biopharmaceutical company
focused on the treatment of diabetes and its complications, today announced a
grant of 150,000 stock options to Richard Pilnik, the Company's newly appointed
Chairman of the Board. The options were awarded in accordance with the Stock
Option Plan at an exercise price of CAD $0.69 and a term of 10 years. The
options are subject to acceptance by the TSX Venture Exchange. 


About DiaMedica

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage
biopharmaceutical company focused on the discovery and development of novel
therapies to treat diabetes and the complications associated with diabetes.
DiaMedica's lead clinical stage product, DM199, is a recombinant human protein
known as rhKLK1 that represents a novel approach to treating diabetes and
associated complications. DiaMedica is also developing a novel monoclonal
antibody, DM204 for the treatment of Type 2 diabetes, which is in preclinical
development.


The Company is listed on the TSX Venture Exchange in Canada under the trading
symbol 'DMA'.


FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, including the intended use of the net proceeds of the Offering,
should be considered forward-looking statements. Such statements are based on
management's exercise of business judgment as well as assumptions made by and
information currently available to management. When used in this document, the
words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and
words of similar import, are intended to identify any forward-looking
statements. You should not place undue reliance on these forward-looking
statements. These statements reflect a current view of future events and are
subject to certain risks and uncertainties as contained in DiaMedica's filings
with Canadian securities regulatory authorities. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results could differ materially from those anticipated in
these forward-looking statements. DiaMedica undertakes no obligation, and does
not intend, to update, revise or otherwise publicly release any revisions to
these forward-looking statements to reflect events or circumstances after the
date hereof, or to reflect the occurrence of any unanticipated events, unless
required by law. Although management believes that expectations are based on
reasonable assumptions, no assurance can be given that these expectations will
materialize.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of the contents of this press
release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica Inc.
John Savage
Chief Financial Officer
763-270-0603
[e-mail]